We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+31.6%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$1.84B
AUM Growth
+$450M
Cap. Flow
+$71.6M
Cap. Flow %
3.89%
Top 10 Hldgs %
79.12%
Holding
28
New
5
Increased
6
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$44.3M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$32.5M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$27.1M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$26.8M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$26.8M

Top Sells

Rank Stock Value
1
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$26.2M
2
CELG
Celgene Corp
CELG
+$21.2M
3
INCY icon
Incyte
INCY
+$17.5M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$16.9M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.92M

Sector Composition

Rank Sector Weight
1 Healthcare 86.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$308M 16.77%
3,998,542
-301,830
-7% -$21.2M
IONS icon
2
Ionis Pharmaceuticals
IONS
$9.4B
$270M 14.71%
7,202,585
-566,587
-7% -$16.9M
GILD icon
3
Gilead Sciences
GILD
$165B
$228M 12.41%
3,627,714
-72,286
-2% -$4.32M
INCY icon
4
Incyte
INCY
$24.4B
$182M 9.89%
4,763,270
-593,879
-11% -$17.5M
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$126B
$106M 5.79%
1,404,445
– –
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$88M 4.79%
757,428
-20,698
-3% -$2.27M
MDVN
7
DELISTED
MEDIVATION, INC.
MDVN
$86.9M 4.73%
2,899,412
– –
ARIA
8
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$67.9M 3.69%
3,689,071
+573,700
+18% +$11.1M
HALO icon
9
Halozyme
HALO
$12.2B
$60.9M 3.31%
5,516,322
-130,197
-2% -$1.08M
IMGN
10
DELISTED
Immunogen Inc
IMGN
$55.8M 3.03%
3,275,816
+13,722
+0.4% +$241K
PCYC
11
DELISTED
PHARMACYCLICS INC
PCYC
$55.2M 3%
+399,030
New +$44.3M
GEVA
12
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$45.3M 2.46%
714,602
+661,053
+1,234% +$32.5M
ONXX
13
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
$42.4M 2.31%
339,870
-206,630
-38% -$26.2M
INVA icon
14
Innoviva
INVA
$1.48B
$36.3M 1.98%
1,102,311
– –
REGN icon
15
Regeneron Pharmaceuticals
REGN
$80.8B
$31.9M 1.74%
+102,000
New +$26.8M
ECYT
16
DELISTED
Endocyte, Inc. Common Stock
ECYT
$30.3M 1.65%
2,269,345
-70,000
-3% -$1.11M
ALNY icon
17
Alnylam Pharmaceuticals
ALNY
$29.3B
$30.2M 1.64%
471,288
+16,488
+4% +$822K
CLVS
18
DELISTED
Clovis Oncology, Inc.
CLVS
$23.2M 1.26%
+381,886
New +$27.1M
INFI
19
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$22.7M 1.23%
1,300,737
+210,909
+19% +$4.04M
NBIX icon
20
Neurocrine Biosciences
NBIX
$16.6B
$22.1M 1.2%
+1,950,148
New +$26.8M
OPTR
21
DELISTED
OPTIMER PHARMACEUTICALS, INC. COM STK
OPTR
$17.9M 0.97%
1,422,200
-24,500
-2% -$325K
TSRO
22
DELISTED
TESARO, Inc.
TSRO
$14.5M 0.79%
+373,300
New +$13.7M
IDIX
23
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
$6.49M 0.35%
1,250,000
– –
ACHN
24
DELISTED
Achillion Pharmaceuticals
ACHN
$5.37M 0.29%
1,779,340
+100,000
+6% +$685K
BMRN icon
25
BioMarin Pharmaceuticals
BMRN
$12.4B
– –
-178,028
Closed -$9.92M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 10.02% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 17.19% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q3 2013 Portfolio in Review

As of Q3 2013, BB Biotech held 28 positions worth $1.84B, up 32% from $1.39B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

BB Biotech deployed $71.6M of net new capital in Q3 2013, opening 5 new positions and adding to 6 existing holdings. Its largest new stake was PHARMACYCLICS INC: 399,030 shares worth $55.2M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 88% a quarter earlier.

On the sell side, the largest reduction was ONYX PHARMACEUTICALS INC, an estimated $26.2M trimmed.

  • BB Biotech's largest Q3 2013 buy was PHARMACYCLICS INC: 399,030 shares worth $55.2M.
  • BB Biotech added most to SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2013, an estimated $32.5M increase.
  • BB Biotech's biggest Q3 2013 reduction was ONYX PHARMACEUTICALS INC, cutting an estimated $26.2M.
  • BB Biotech fully exited BioMarin Pharmaceuticals in Q3 2013, selling an estimated $9.92M.
  • BB Biotech's ten largest holdings make up 79% of its $1.84B portfolio in Q3 2013.
  • BB Biotech opened 5 new positions and closed 4 in Q3 2013.
  • BB Biotech's portfolio value rose 32% quarter-over-quarter to $1.84B.

Based on BB Biotech's 13F filing for Q3 2013, filed 12 Nov 2013.